2 studies show CRISPR might drive up cancer risk in edited cells

13 June 2018

Amirah Al Idrus / FierceBiotech

Off-target, or unintended, editing is a key safety concern of CRISPR-Cas9, as it can lead to cancer and other side effects. Two new studies show that CRISPR editing could raise the risk of targeted cells—those being edited to treat disease—developing tumors.

A pair of studies published Monday found that CRISPR editing triggers a mechanism that protects cells from DNA damage. Cells that have this protective system are harder to edit, while cells lacking it are easier to edit. The catch? Cells that are easy to edit could be more susceptible to cancer-causing mutations.

“We managed to edit cancer cells easily, but when we tried to edit normal, healthy cells, very little happened,” said Emma Haapaniemi, of the Karolinska Institutet in Sweden. What’s more, about half of all cancer cells do not have this protective pathway, the researchers said.

“When we looked at this further, we found that cutting the genome with CRISPR-Cas9 induced the activation of a protein known as p53, which acts like a cell’s alarm system, signalling that DNA is damaged, and opens the cellular ‘first aid kit’ that repairs damage to the DNA. The triggering of this system makes editing much more difficult,” said Haapaniemi, the first author of one of the studies, published in Nature Medicine. The other study, by Novartis, came to similar conclusions.

Editing cells without this “alarm system” could eventually boost the number of cells without protection against DNA damage. Blocking p53 in healthy cells slated for editing might be one way to “decrease the risk of selecting for p53-deficient cells,” but it could still open them up temporarily to mutations that cause cancer.

The news drove down stocks for CRISPR biotechs—CRISPR Therapeutics, Editas and Intellia, to name a few. And while the researchers are calling for more work to determine whether CRISPR editing “may inadvertently raise cancer risk in cells,” they also said it’s hardly time to panic. After all, CRISPR has weathered a couple of storms, including a 2017 study saying the technology caused masses of off-target effects that was retracted this year.

“We don’t want to sound alarmist, and are not saying that CRISPR-Cas9 is bad or dangerous. This is clearly going to be a major tool for use in medicine, so it’s important to pay attention to potential safety concerns. Like with any medical treatment, there are always side effects or potential harm and this should be balanced against the benefits of the treatment,” said Jussi Taipale, of the University of Cambridge, who led the work while at the Karolinska Institutet.


Previous publication Next publication

Media Center

  • 23 October 2018

    Genomic Health Announces Multiple Studies Reinforcing Value of Oncotype DX® Tests in Guiding Treatment for Breast and Prostate Cancer Patients

    Genomic Health, Inc. (Nasdaq: GHDX) today announced results from multiple studies of its Oncotype DX® tests highlighting their value in optimizing treatment for patients with various stages of breast and prostate cancer. The findings, presented at the ESMO 2018 Congress in Munich, Germany, demonstrated that the Oncotype DX tests identify patients who will or will not benefit from a specific treatment.

  • 23 October 2018

    Russian cancer drug based on smallpox vaccine undergoes preclinical studies

    Siberian scientists have brought to the final stage of preclinical testing the only Russian therapeutic cancer drug. This part of the study is expected to be completed by the end of 2019, according to Sergei Netesov, Chairman of the Board of the Association for the Development of the Innovative Territorial Cluster of the Novosibirsk Region in the Sphere of Biopharmaceutical Technologies (‘Biopharm’).

  • 22 October 2018

    Pfizer preps for BMS showdown with Bavencio kidney cancer combo data

    Pfizer has long been a player in kidney cancer, but it’s looking to take things up a notch—and challenge next-gen rival Bristol-Myers Squibb—with its latest data. Sunday at the European Society for Medical Oncology annual meeting, the New York drugmaker and partner Merck KGaA said their immuno-oncology agent Bavencio, in tandem with Pfizer’s Inlyta, had staved off cancer progression in previously untreated patients by a median 13.8 months, compared with 8.4 months for standard-of-care Sutent, another Pfizer drug.

  • 19 October 2018

    FDA Publishes Guidance on the Rare Disease Treatments

    FDA published draft guidance on October 15, 2018 to assist sponsors developing treatments for rare diseases plan for pre-investigational new drug application (pre-IND) meetings with FDA. In the guidance, the agency describes topics that should be considered in early drug development and pre-IND meetings.

Read more